| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LAPTM4A |
| Uniprot No | Q15012 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-233aa |
| 活性数据 | MVSMSFKRNRSDRFYSTRCCGCCHVRTGTIILGTWYMVVNLLMAILLTVEVTHPNSMPAVNIQYEVIGNYYSSERMADNACVLFAVSVLMFIISSMLVYGAISYQVGWLIPFFCYRLFDFVLSCLVAISSLTYLPRIKEYLDQLPDFPYKDDLLALDSSCLLFIVLVFFALFIIFKAYLINCVWNCYKYINNRNVPEIAVYPAFEAPPQYVLPTYEMAVKMPEKEPPPPYLPA |
| 分子量 | 53.2 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人LAPTM4A蛋白的示例参考文献(部分为模拟内容，供参考)：
---
1. **"LAPTM4A promotes chemoresistance in breast cancer via lysosomal modulation"**
- 作者：Li, X.; Zhang, Y.; et al.
- 摘要：研究揭示了重组人LAPTM4A蛋白通过调节溶酶体功能增强乳腺癌细胞对阿霉素的耐药性，其过表达抑制药物在溶酶体内的累积，为肿瘤耐药机制提供了新视角。
2. **"Expression and purification of recombinant human LAPTM4A for functional studies"**
- 作者：Chen, J.; Wang, H.; et al.
- 摘要：报道了一种高效的大肠杆菌表达系统纯化重组人LAPTM4A蛋白的方法，并证实其体外能结合磷酸肌醇，为后续结构及互作研究奠定基础。
3. **"LAPTM4A interacts with mTOR signaling to regulate autophagy in hepatocellular carcinoma"**
- 作者：Liu, R.; Zheng, S.; et al.
- 摘要：通过重组LAPTM4A蛋白的体外实验，发现其通过mTOR通路调控肝癌细胞自噬水平，促进肿瘤细胞存活，提示其作为治疗靶点的潜力。
4. **"Structural insights into LAPTM4A-mediated lipid transport"**
- 作者：Smith, T.J.; Brown, K.E.
- 摘要：通过冷冻电镜解析重组人LAPTM4A蛋白的结构，揭示其跨膜区形成脂质结合口袋，解释了其在胆固醇转运中的作用，关联溶酶体膜稳定性与疾病发生。
---
*注：以上文献为示例性质，实际引用需以真实出版物为准。建议通过PubMed、Web of Science等平台检索最新文献。*
Recombinant human LAPTM4A (Lysosomal Protein Transmembrane 4 Alpha) is a protein encoded by the *LAPTM4A* gene, which belongs to the LAPTM family involved in lysosomal function and transmembrane transport. LAPTM4A is primarily localized to lysosomal and endosomal membranes, where it modulates processes like lysosomal acidification, cargo sorting, and vesicle trafficking. It interacts with signaling molecules, lipids, and cations, influencing cellular homeostasis, autophagy, and growth regulation. Dysregulation of LAPTM4A has been linked to cancer progression, including enhanced proliferation, metastasis, and chemoresistance in malignancies such as breast, lung, and gastric cancers. Its overexpression is associated with aberrant activation of pathways like PI3K/AKT/mTOR.
The recombinant form of LAPTM4A is produced using heterologous expression systems (e.g., mammalian or bacterial cells) for in vitro and in vivo studies. It enables researchers to dissect its molecular interactions, structure-function relationships, and roles in disease mechanisms. Recombinant LAPTM4A is crucial for developing therapeutic strategies targeting its pathways or for diagnostic applications as a biomarker. Studies using this protein have advanced understanding of lysosomal biology and its intersection with oncogenic processes, offering potential avenues for precision medicine in oncology.
×
